HOME › DRUGS › SATRALIZUMAB
ACTIVE SUBSTANCE / INN

SATRALIZUMAB

Brand name(s): Enspryng, ENSPRYNG
FDA LISTED
EMA LISTED
PRESCRIPTION
AUTHORISED
Neuromyelitis Optica
BLA761149
ACTIVE SUBSTANCE
Satralizumab
REGULATORS
FDA · EMA
SPONSORS / MAH
GENENTECH, Roche Registration GmbH
TOTAL APPLICATIONS
2
FDA APPLICATIONS (DRUGS@FDA)
BRAND NAMEAPPLICATIONSPONSORSTATUS
ENSPRYNGBLA761149GENENTECHPrescription
EMA AUTHORISATIONS
PRODUCT NAMEHOLDERSTATUSDATEINDICATION
EnspryngRoche Registration GmbHAuthorised24/06/2021Neuromyelitis Optica

FULL INTELLIGENCE ON SATRALIZUMAB

Patent cliffs, clinical trials, pipeline data, AI-enriched regulatory signals — free on PharmaSignal.

OPEN PLATFORM →